Rigel Pharmaceuticals, Inc.
General ticker "RIGL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $627.8M (TTM average)
Rigel Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 29.6%.
Estimated limits based on current volatility of 2.2%: low 46.42$, high 48.49$
Factors to consider:
- Total employees count: 174 (+7.4%) as of 2025
- Top business risk factors: Market opportunity smaller than estimated, Insufficient infrastructure, Clinical trial failure, Regulatory and compliance, Market competition
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [25.14$, 44.13$]
- 2026-12-31 to 2027-12-31 estimated range: [24.39$, 43.06$]
Financial Metrics affecting the RIGL estimates:
- Positive: with PPE of 6.7 at the end of fiscal year the price was neutral
- Positive: 8.77 < Operating cash flow per share per price, % of 9.64
- Negative: Investing cash flow per share per price, % of -11.77 <= -11.23
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: Return on assets ratio (scaled to [-100,100]) of 41.68 > 10.70
- Positive: Operating profit margin, % of 42.63 > 33.79
- Positive: Interest expense per share per price, % of 0.93 <= 1.42
- Negative: 0 < Industry inventory ratio change (median), % of 0
Short-term RIGL quotes
Long-term RIGL plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $116.88MM | $179.28MM | $294.28MM |
| Operating Expenses | $137.37MM | $155.09MM | $168.82MM |
| Operating Income | $-20.49MM | $24.19MM | $125.47MM |
| Non-Operating Income | $-4.60MM | $-5.83MM | $-3.64MM |
| Interest Expense | $6.87MM | $7.92MM | $7.32MM |
| R&D Expense | $24.52MM | $23.38MM | $33.30MM |
| Income(Loss) | $-25.09MM | $18.37MM | $121.83MM |
| Taxes | $0.00MM | $0.88MM | $-245.20MM |
| Net Income(Loss)* | $-25.09MM | $17.48MM | $367.02MM |
| Stockholders Equity | $-28.64MM | $3.29MM | $391.48MM |
| Inventory | $5.52MM | $6.00MM | $11.51MM |
| Assets | $117.22MM | $163.98MM | $513.59MM |
| Operating Cash Flow | $-5.74MM | $31.47MM | $75.66MM |
| Capital expenditure | $15.00MM | $0.40MM | $0.00MM |
| Investing Cash Flow | $-4.30MM | $4.13MM | $-92.36MM |
| Financing Cash Flow | $18.37MM | $-11.64MM | $0.60MM |
| Earnings Per Share** | $-1.44 | $0.99 | $20.40 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.